Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery focuses on US expansion with the Appointment of Dr Bruce Sargent

Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has appointed Dr Bruce Sargent as Strategic Business Development Lead for North America to assist with the company’s ambitious growth plans for the USA and Canada.

Sygnature Discovery is expanding its business development presence in the USA and Dr Sargent will play an instrumental part of this expansion.

Dr Sargent is a highly-experienced drug discoverer with more than 35 years in drug discovery and development, including 20 years at Boots plc in Nottingham.  He has a proven track record of leading multiple programmes that have delivered drugs into development and will be leveraging his substantial experience to provide local support for Sygnature’s existing and developing US-located client base.  Sygnature will also be utilising Dr Sargent’s business leadership experience to help them with their US business development strategy.

On his appointment, Dr Sargent commented:

“I am delighted to be working with Sygnature Discovery – particularly at such an exciting time in their business expansion plans. Sygnature afford a breadth of capability supported by substantial experience that is rare amongst drug discovery service providers, positioning them in the top class for executing integrated programs. I am proud to be part of the team”

As part of planned expansion of the company’s business development function, Sygnature Discovery is in the process of recruiting additional US-based business developers, who will work closely with Dr Sargent and the business development and marketing team based in BioCity Nottingham.  These newly-created business development roles will be based on the US East and West Coasts and the selected candidates will be responsible for increasing Sygnature’s client base and sales in North America.

Founder and CEO of Sygnature Discovery, Dr Simon Hirst commented:

“Since its foundation in 2004, Sygnature Discovery has always had clients in the USA.  However, to effectively develop even more business opportunities in North America, we need to expand our business development team so that we have a permanent presence there, situated in areas where cutting-edge drug discovery is taking place.  Adding US-based business developers who are scientists at heart will boost our existing activities to win new clients and ensure that we stay on track with our ambitious expansion plans.”

Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.